Introduction

Risk-benefit analysis in biotechnology approvals is the systematic evaluation of a proposed biotechnology product’s expected benefits against its potential risks to human health, the environment, and society. It is important in approving genetically modified (GM) crops, gene therapies, vaccines, and other biotechnology products.

The analysis examines whether a product offers meaningful benefits, whether its risks are scientifically acceptable, and whether those risks can be reduced through safeguards. For example, a GM crop may promise higher yields or reduced pesticide use, but regulators must also consider possible gene flow, effects on non-target organisms, food safety, and long-term environmental consequences.

In India, biotechnology approvals are governed by legislation including the Environment (Protection) Act, 1986, and the Rules of 1989 on genetically engineered organisms. Risk-benefit analysis must be scientific, transparent, case-specific, and consistent with the precautionary principle. A claimed benefit cannot automatically justify a serious or inadequately assessed risk.

Legal Framework and Case Laws

1. Gene Campaign v. Union of India, 2024 INSC 545

The Supreme Court examined the conditional environmental approval of genetically modified mustard (DMH-11). The case involved questions concerning biosafety assessment, environmental effects, and the precautionary principle.

The Court discussed the need to evaluate both the potential benefits and risks of GM crops through a scientifically sound process. The judgment referred to case-specific risk assessment, risk management, and risk communication. It also highlighted that scientific uncertainty should be addressed through further information, appropriate safeguards, or monitoring.

The Bench delivered separate opinions and differed on the validity of the approval. The approval issue was referred for fresh consideration. The judgment also cautioned that courts are not ordinarily equipped to conduct the executive’s scientific or policy cost-benefit analysis themselves; their role is to review legality and compliance with constitutional and statutory requirements.

Sci API+2

2. Vellore Citizens’ Welfare Forum v. Union of India, (1996) 5 SCC 647

The Supreme Court recognised the precautionary principle as part of Indian environmental law. It held that where serious or irreversible environmental harm is threatened, lack of complete scientific certainty cannot justify postponing preventive measures.

This principle limits risk-benefit analysis: anticipated economic or technological benefits cannot automatically outweigh a credible threat of serious environmental damage. Regulators must consider preventive safeguards and the consequences of uncertainty.

VoxJuris

3. A.P. Pollution Control Board v. Prof. M.V. Nayudu, (1999) 2 SCC 718

The Supreme Court emphasised the role of scientific expertise in environmental decision-making, particularly where risks are technically complex or uncertain.

The case supports the use of independent experts, reliable data, and careful evaluation before approving potentially harmful activities. It is relevant by analogy to biotechnology approvals, where the regulator must understand both the expected benefits and the possible adverse effects.

Essential Elements of Risk-Benefit Analysis

A proper analysis should consider:

Expected benefit: The product’s therapeutic, agricultural, or scientific value.

Risk probability and severity: The likelihood and seriousness of possible harm.

Alternatives: Existing treatments, technologies, or safer options.

Uncertainty: Missing data and unknown long-term effects.

Mitigation: Whether risks can be reduced through containment, monitoring, or restrictions.

Proportionality: Whether the expected benefit reasonably justifies the remaining risk.

Conclusion

Risk-benefit analysis is central to lawful biotechnology approval. It requires regulators to evaluate scientific evidence, potential benefits, adverse consequences, and available safeguards. Gene Campaign demonstrates the importance of transparent and case-specific biosafety assessment, while Vellore Citizens’ Welfare Forum establishes that serious environmental risks cannot be ignored merely because scientific certainty is incomplete. A.P. Pollution Control Board v. Nayudu reinforces the need for expert evaluation. Ultimately, biotechnology approval must be evidence-based, proportionate, and open to review as new information emerges.